Spectral Medical Inc.

The U.S. FDA has accepted Spectral’s PMA application for PMX. The application is supported by the Phase 3 TIGRIS trial, which met its primary endpoint and demonstrated sustained survival benefit through 12 months. 👉 buff.ly/0t63AsE #Sepsis #SepticShock #CriticalCare

Spectral Medical announces the closing of the first tranche of its C$14M convertible note private placement. Proceeds are intended for repayment of maturing debt and general corporate and working capital purposes. Full release: buff.ly/E3u5koY

10 experts. 20 consensus statements on patient assessment, EAA interpretation and PMX-HA use in endotoxic septic shock. A framework to support preparation for potential U.S. adoption, pending FDA approval. link.springer.com/article/10… #MedEd

In case you missed it: patient selection and study design take centre stage in this episode of Cappuccino with Claudio Ronco. Don’t miss the conversation: youtube.com/watch?v=HwIQ_eyG… #ClinicalTrial $EDT.TO

Viruses do not produce endotoxin. So how can it become relevant in viral sepsis? Secondary Gram-negative infections and gut barrier dysfunction are two potential routes. Watch the video to explore the connection. buff.ly/c3hunSl

In abdominal septic shock, which patients may benefit from targeted endotoxin removal? 👉 buff.ly/gygfp9t

These findings illustrate the consequences of sepsis across the continuum of care and reinforce the urgency of earlier recognition, better identification of its biological drivers, and more precise treatment strategies for patients at highest risk. Ref: buff.ly/mGhlu91

These figures reinforce the urgency of improving early recognition, identifying the biological drivers of sepsis, and advancing more precise treatment strategies for patients at highest risk. Read the updated AHRQ data: buff.ly/KzYXpMG #SepsisAwarenessMonth

This World Sepsis Day, we join the global sepsis community in raising awareness of a condition that affects millions of people and families every year. Learn more about World Sepsis Day and how you can support the global campaign: buff.ly/hHQpEh6 #WSD2026 #Sepsis

Spectral Medical is pleased to provide an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration regarding the Premarket Approval application for Toraymyxin™ (PMX). Read the full news release: spectraldx.com/spectral-medi…

This September, learn the signs, share the facts, and join us in driving the awareness needed to transform patient outcomes. Explore Sepsis Alliance resources and discover more ways to get involved: sepsis.org/get-involved/seps…

Critical care nurses play a central role in sepsis recognition, treatment and research. Join us for a nurse-led discussion and two days of expert perspectives and practical insights at the virtual Sepsis Alliance Sepsis Summit. Registration is free: buff.ly/y9YOH6L

Join us in supporting Sepsis Alliance this September by sharing educational resources, getting involved in your community or taking part in the Sepsis Superhero Challenge. Explore the many ways you can help: buff.ly/vXg7pqx #SAM2026 #15YearsOfSAM

Spectral Medical reported Q2 2026 results, highlighted by submission and formal filing of its PMA application for PMX with the FDA. The Company also advanced preparations for anticipated pre-approval inspections and potential U.S. commercialization. 👉spectraldx.com/spectral-medi…

John Kellum: Getting into the end zone pittmed.pitt.edu/news/john-k…

New expert consensus in Critical Care examines patient selection, EAA-guided decision-making and PMX-HA in endotoxic septic shock, highlighting how clinical context and biomarker insight may help identify patients for targeted therapy. 👉 buff.ly/DhQC9X8 #FOAMed

In sepsis, the host response can be both protective and harmful. A recent review examines how the same mechanisms that defend against infection may drive cellular and organ dysfunction when the response becomes overwhelmed. buff.ly/7Zx0b5n #MedEd #SepsisResearch

In the latest episode of Cappuccino with Claudio Ronco, Prof. Ronco and Spectral Medical CMO Dr. John Kellum discuss the TIGRIS trial, Bayesian methodology, and patient selection in endotoxic septic shock. Don't miss the conversation: buff.ly/XiDnjeC #CriticalCare

Under LPS-stimulated conditions, PMX preferentially adsorbed activated granulocytes and neutrophils and reduced the neutrophil-to-lymphocyte ratio. These findings are hypothesis-generating, and their clinical relevance remains to be determined. 👉 buff.ly/g9XGiG3

Sepsis is not one disease. A new Journal of Intensive Care review highlights biomarker-guided care, including EAA™-identified endotoxic septic shock and PMX hemoadsorption in selected patients, citing TIGRIS as part of the evolving evidence. buff.ly/6TQnSFP #SepticShock

We’re proud to congratulate our Chief Medical Officer, Dr. John Kellum, on his induction as a Fellow of the National Academy of Inventors. His pioneering work in sepsis, acute kidney injury, biomarkers and precision-guided care continues to shape critical care medicine. #NAI